Free Trial
NASDAQ:HSIC

Henry Schein (HSIC) Stock Price, News & Analysis

$73.47
-1.13 (-1.51%)
(As of 05/20/2024 ET)
Today's Range
$73.20
$74.60
50-Day Range
$67.78
$75.52
52-Week Range
$60.01
$82.63
Volume
800,946 shs
Average Volume
1.07 million shs
Market Capitalization
$9.41 billion
P/E Ratio
24.82
Dividend Yield
N/A
Price Target
$81.73

Henry Schein MarketRank™ Stock Analysis

Analyst Rating
Hold
2.36 Rating Score
Upside/​Downside
11.2% Upside
$81.73 Price Target
Short Interest
Healthy
3.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.42
Upright™ Environmental Score
News Sentiment
1.19mentions of Henry Schein in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$693,814 Sold Last Quarter
Proj. Earnings Growth
9.25%
From $5.08 to $5.55 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.53 out of 5 stars

Medical Sector

174th out of 918 stocks

Medical & Hospital Equipment Industry

3rd out of 3 stocks

HSIC stock logo

About Henry Schein Stock (NASDAQ:HSIC)

Henry Schein, Inc. provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products, such as branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners; and value-added practice solutions comprising practice consultancy, education, revenue cycle management and financial services, e-services, practice technology, and network and hardware services, as well as consulting, and continuing education services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

HSIC Stock Price History

HSIC Stock News Headlines

Expert Outlook: Henry Schein Through The Eyes Of 7 Analysts
Q1 2024 Henry Schein Inc Earnings Call
Henry Schein: Q1 Earnings Snapshot
Henry Schein Inc. Q1 Profit Decreases, but beats estimates
Goldman’s debt issuers stocks basket
Henry Schein Celebrates Earth Day 2024
See More Headlines
Receive HSIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Henry Schein and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/07/2024
Today
5/20/2024
Next Earnings (Estimated)
8/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical & hospital equipment
Sub-Industry
Health Care Distributors
Current Symbol
NASDAQ:HSIC
CUSIP
80640710
Employees
25,000
Year Founded
1932

Price Target and Rating

Average Stock Price Target
$81.73
High Stock Price Target
$96.00
Low Stock Price Target
$65.00
Potential Upside/Downside
+11.2%
Consensus Rating
Hold
Rating Score (0-4)
2.36
Research Coverage
11 Analysts

Profitability

Net Income
$416 million
Pretax Margin
4.06%

Debt

Sales & Book Value

Annual Sales
$12.34 billion
Cash Flow
$6.58 per share
Book Value
$33.01 per share

Miscellaneous

Free Float
126,591,000
Market Cap
$9.41 billion
Optionable
Optionable
Beta
0.87

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

HSIC Stock Analysis - Frequently Asked Questions

Should I buy or sell Henry Schein stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 1 sell rating, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HSIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HSIC, but not buy additional shares or sell existing shares.
View HSIC analyst ratings
or view top-rated stocks.

What is Henry Schein's stock price target for 2024?

11 brokerages have issued 1 year price targets for Henry Schein's shares. Their HSIC share price targets range from $65.00 to $96.00. On average, they anticipate the company's share price to reach $81.73 in the next twelve months. This suggests a possible upside of 11.2% from the stock's current price.
View analysts price targets for HSIC
or view top-rated stocks among Wall Street analysts.

How have HSIC shares performed in 2024?

Henry Schein's stock was trading at $75.71 at the start of the year. Since then, HSIC shares have decreased by 3.0% and is now trading at $73.47.
View the best growth stocks for 2024 here
.

When is Henry Schein's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our HSIC earnings forecast
.

How were Henry Schein's earnings last quarter?

Henry Schein, Inc. (NASDAQ:HSIC) issued its quarterly earnings results on Tuesday, May, 7th. The company reported $1.10 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.09. The firm earned $3.17 billion during the quarter, compared to analysts' expectations of $3.21 billion. Henry Schein had a net margin of 3.12% and a trailing twelve-month return on equity of 13.51%. The business's revenue was up 3.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.21 EPS.
Read the conference call transcript
.

When did Henry Schein's stock split?

Shares of Henry Schein split before market open on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly minted shares were distributed to shareholders after the closing bell on Thursday, September 14th 2017. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

How will Henry Schein's stock buyback program work?

Henry Schein declared that its board has authorized a share repurchase program on Thursday, August 18th 2022, which authorizes the company to buyback $400,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 4% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's leadership believes its stock is undervalued.

What guidance has Henry Schein issued on next quarter's earnings?

Henry Schein updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of 5.000-5.160 for the period, compared to the consensus EPS estimate of 5.060. The company issued revenue guidance of $13.3 billion-$13.6 billion, compared to the consensus revenue estimate of $13.4 billion.

What is Stanley M. Bergman's approval rating as Henry Schein's CEO?

451 employees have rated Henry Schein Chief Executive Officer Stanley M. Bergman on Glassdoor.com. Stanley M. Bergman has an approval rating of 94% among the company's employees. This puts Stanley M. Bergman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Henry Schein own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Henry Schein investors own include Alibaba Group (BABA), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Intel (INTC), NVIDIA (NVDA), QUALCOMM (QCOM), CVS Health (CVS), Micron Technology (MU) and AT&T (T).

Who are Henry Schein's major shareholders?

Henry Schein's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (12.01%), Perpetual Ltd (1.88%), Lazard Asset Management LLC (1.79%), Nuance Investments LLC (1.37%), Burgundy Asset Management Ltd. (1.26%) and Pzena Investment Management LLC (0.77%). Insiders that own company stock include Bradford C Connett, David B Brous Jr, Gerald A Benjamin, James P Breslawski, Kurt P Kuehn, Lorelei Mcglynn, Mark E Mlotek, Michael S Ettinger, Philip A Laskawy, Scott Philip Serota, Stanley M Bergman and Walter Siegel.
View institutional ownership trends
.

How do I buy shares of Henry Schein?

Shares of HSIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Henry Schein have any subsidiaries?
The following companies are subsidiares of Henry Schein: ACE Surgical Supply Co. Inc., ADS Florida, AUV Veterinary Services, Accord, Alpha Scientific, Arcade Dentaire, Arseus, Arseus Dental Solutions, Arseus Lab, Becker-Parkin Dental Supply, BioHorizons Inc., Butler Schein Animal Health, C&M Vetlink, Camlog USA Inc., DNA Anthos Impianti, Dental Cremer, Dental Trey, Elite Computer Italia, Exan Enterprises Inc., HS Brand Management LLC, HS TM Holdings LLC, HSFR Inc., Handpiece Parts & Repairs Inc., Henry Schein Europe Inc., Henry Schein Global Sourcing Inc., Henry Schein Latin America Pacific Rim Inc., Henry Schein Medical Systems Inc., Henry Schein Practice Solutions Inc., InSource Inc., Jorgen Kruuse, Lincoln Dental Supply, Logiciel Julie, Maddox Practice Group, Maravet, Marrodent, Medivet, Medka, Minerva Dental Limited, Modern Laboratory Services, NLS Animal Health, Noviko, Ortho Organizers, Ortho Technology, Prism Medical Products L.L.C., Prism Medical Products LLC, Project Helium Holdings LLC, Project Spartan Holdings Corp., RxWorks, SG Healthcare Corp., Sirona Direct, SmartPak Equine LLC, Software of Excellence, Sogim Grimouille, Southern Anesthesia & Surgical, S & S Discount Inc., TDSC Inc., The Exan Group, Veterinary Instrumentation, Vetstreet, W. & J. Dunlop, eAssist Inc., and scil animal care.
Read More
This page (NASDAQ:HSIC) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners